Sharekhan

#SharekhanResearch #Q4FY22 Pharma Review- weak qtr, strng gwth in India bizz, US gwth muted while cost pressures st… https://t.co/UaomdfPjBF #SharekhanResearch #Q4FY22

#SharekhanResearch retains Buy on #Lupin (12month PT Rs780) #Q4Fy22 was weak qtr, OPM’s surprise -vely; healthy pro… https://t.co/7pYGb1UHp3 #SharekhanResearch #Lupin #Q4Fy22

#SharekhanResearch retains Hold on #Granules (12month PT Rs290) #Q4FY22 was a weak qtr; cost headwinds & uncertaint… https://t.co/hKZUv0HBmp #SharekhanResearch #Granules #Q4FY22

#SharekhanResearch retains Buy on #AbbottIndia (12mth PT Rs22780) #Q4 was a strng qtr, backed by multiple gwth leve… https://t.co/x9RYJhAMTM #SharekhanResearch #AbbottIndia #Q4

#SharekhanResearch retains Positive view on #CaplinPoint (Upside 35%) #Q4 was a strong quarter; focus to strengthen… https://t.co/PIVL9KCmDT #SharekhanResearch #CaplinPoint #Q4

#SharekhanResearch retains Buy rating on #Cipla (12month PT Rs 1150) adjusting for one offs #Q4FY22 was operational… https://t.co/NNrztNTBvb #SharekhanResearch #Cipla #Q4FY22

#SharekhanResearch retain Buy on Gateway Distriparks with PT of Rs91, Operationally in-line #Q4FY22, Net debt down… https://t.co/8KOnWlb11g #SharekhanResearch #Q4FY22

#SharekhanResearch NBFC #Q4FY2021 Review – Strong Q4 & FY2021 for NBFCs across board and an improving trend on grow… https://t.co/3df5r7OgqS #SharekhanResearch #Q4FY2021

#SharekhanResearch maintains Positive View on IDFC Ltd and see 20-25% upsides; Healthy #Q4FY2021earnings with Asset… https://t.co/FgnfRUS4Pu #SharekhanResearch #Q4FY2021earnings